SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: The Ox1/31/2008 10:02:19 PM
  Read Replies (1) of 8239
 
CTIC came up on a scan tonight, fwiw. I know nothing about the company.

EDIT:

Cell Therapeutics says Zevalin cancer drug effective as consolidation therapy



SEATTLE (Thomson Financial) - Cell Therapeutics Inc said its cancer drug
Zevalin was well tolerated and effective in a phase II clinical study which saw
radioimmunotherapy (RIT) added to chemotherapy for previously untreated patients
with non-follicular indolent non-Hodgkin's lymphoma.
The results, published in the journal CANCER, showed that the addition of
RIT to chemotherapy in this trial produced a 100 pct complete remission at end
of treatment with an estimated 89 pct of patients remaining in remission at
three years.
Cell Therapeutics bought Zevalin from Biogen Idec Inc last year and is to
pay royalties to Biogen based on Zevalin's net sales until at least Dec 2015.
tf.TFN-Europe_newsdesk@thomson.com

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News